Licensing in Antibacterial R and D - Filling the Gaps

Introduction:

Increasing drug-resistance, alongside growing competition and increasing costs of discovery, is decreasing the incentive to invest in novel antibacterial product development. As such, the R&D pipelines of many key companies are currently relatively weak. In order to maintain future market share, leading companies will need to seek innovation through licensure and partnership. 

Scope:

* Analysis of the key drivers and resistors of licensing deals and partnership in antibacterial R&D. 

* Overview of licensing activity in the antibacterial market, with particular emphasis on the leading five companies 

* Current and projected future antibacterial portfolio reliance on licensed products 

Report Highlights:

Patent expiries and drug resistance will lead to decreased revenues from current antibacterial products. The lack of promising in-house R&D projects means that licensing is the only option for many key players looking to maintain market share 

Large pharmaceutical companies generally operate across multiple therapy areas, with antibacterial revenue forming only a small component of total ethical sales. Licensing offers a lower risk strategy for maintaining franchise sales, particularly where resource allocation to antibacterial R&D is limited. 

Companies reliant on licensed products will generally demonstrate greater antibacterial growth to 2011. Aventis’ portfolio sales, however, will demonstrate the greatest increase, demonstrating the strength of its in-house resources. 

Reasons to Purchase:

* Understand the key drivers and resistors of R&D licensing in antibacterials. 

* Identify companies heavily reliant on licensed products in 2002 and 2011. 

* Determine which players will need to in-license compounds in order to maintain market share. 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a222